Press release
Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Eczema Research. Learn more about our innovative pipeline today! @ Eczema Pipeline Outlook [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Eczema Pipeline Report
* June 2024:- LEO Pharma- A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema. The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).
* June 2024:- AnaptysBio Inc.- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis. This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD). This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
* DelveInsight's Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
* The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
* Eczema Therapies such as Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.
Stay informed about the cutting-edge advancements in Eczema Treatments. Download for updates and be a part of the revolution in dermatology care @ Eczema Clinical Trials Assessment [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eczema Emerging Drugs Profile
* Amlitelimab: Kymab
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases.
* BX 005: BiomX
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
* LP 0145: LEO Pharma
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.
Learn more about Eczema Drugs opportunities in our groundbreaking Eczema Research and development projects @ Eczema Unmet Needs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eczema Companies
Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Eczema Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Eczema Treatment by visiting our website. Stay informed about how we're transforming the future of dermatology disease @ Eczema Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Eczema Pipeline Report
* Coverage- Global
* Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
* Eczema Therapies-Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Eczema Pipeline on our website @ Eczema Drugs and Companies [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Eczema: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Eczema- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Amlitelimab: Kymab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Eczema Key Companies
* Eczema Key Products
* Eczema- Unmet Needs
* Eczema- Market Drivers and Barriers
* Eczema- Future Perspectives and Conclusion
* Eczema Analyst Views
* Eczema Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3564777 • Views: …
More Releases from ABNewswire
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise…
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card.
The book draws on Zeitoun-Sedki's years of representing individuals and families from…
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity.
Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg
Automotive OBD Products and Application Scenarios
As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions…
More Releases for Eczema
Global Parents for Eczema Research (GPER) Announces 2025 Childhood Eczema Preven …
Santa Barbara, CA, September 9, 2025 - A decade ago, Global Parents for Eczema Research (GPER) was founded with a simple but powerful mission: to reduce the suffering of children with eczema and to give parents a voice in shaping research priorities. Today, GPER is carrying that mission forward by directly funding innovative science to make rapid progress towards a cure and prevention.
GPER is excited to announce the recipients of…
Hand Eczema Market Massive Growth opportunity Ahead
Introduction
Hand eczema, a chronic inflammatory skin condition affecting the hands, is one of the most common occupational skin disorders worldwide. Characterized by itching, redness, scaling, and painful cracks, it can severely impair daily activities and quality of life. The condition is prevalent among healthcare workers, hairdressers, construction workers, and others exposed to irritants and allergens.
With increasing awareness of skin health, growth in dermatological research, and the introduction of novel therapies…
Codex Labs to Exhibit at the National Eczema Association's Eczema Expo 2025
Scottsdale, Ariz. - July 17th, 2025 - Codex Labs [https://www.codexlabscorp.com/], a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in the National Eczema Association's Eczema Expo 2025 [https://nationaleczema.org/eczema-expo/?gad_source=1&gad_campaignid=22351487646&gbraid=0AAAAAB0npNbWbfjE80zPi-DhIw2YfY2qF&gclid=CjwKCAjw3f_BBhAPEiwAaA3K5GPLZHZHEl6Qy8xrAj3hEWhfW7WDsCE-7pymOFKmLfLmr43e1AAXYhoC90YQAvD_BwE]. Taking place from July 24th to 27th at the Grand Hyatt Scottsdale Resort, individuals impacted by eczema will gather to learn from world-class medical experts and community leaders. The goal of the event is to provide you with support,…
Global Parents for Eczema Research (GPER) Awards Two Grants to Advance Childhood …
Santa Barbara, CA, October 15, 2024 - Global Parents for Eczema Research (GPER), a nonprofit organization dedicated to improving the lives of children suffering from eczema (atopic dermatitis, AD), announced the funding of two groundbreaking research projects as part of its 2024 Childhood Eczema Prevention Grant program. These grants will each provide up to $25,000 to support clinical research focused on preventing eczema in children.
Eczema affects up to 20% of…
Global Parents for Eczema Research (GPER) Announces Childhood Eczema Prevention …
Santa Barbara, CA, March 11, 2024 - Global Parents for Eczema Research (GPER) today announced the release of its Childhood Eczema Prevention Grant aimed at supporting innovative research studies focused on preventing pediatric atopic dermatitis (AD or "eczema"). This funding announcement is aimed at addressing the increasing prevalence of AD among children and at fostering research initiatives with the potential to mitigate the burden on children and families.
"We are dedicated…
Eczema Treatment Market During 2017 to 2025
Eczema, also referred as dermatitis or atopic dermatitis, is a disease which results in inflammation of the skin. Eczema is characterized by rash, red skin, and itchiness. The area of the skin involved may vary from small to the entire body. Few combination of factors such as genetical factor, abnormal function of immune system, environmental factor, defects in skin barrier, and activities may cause the skin to be extremely sensitive.…
